Literature DB >> 3721406

The grading of rectal cancer: historical perspectives and a multivariate analysis of 447 cases.

J R Jass, W S Atkin, J Cuzick, H J Bussey, B C Morson, J M Northover, I P Todd.   

Abstract

The grade of a tumour is gauged on the subjective assessment of a number of histopathological parameters. The problems associated with this exercise were viewed from a historical perspective and survival analysis of 447 patients receiving surgery for rectal adenocarcinoma was undertaken. Only deaths from rectal adenocarcinoma were included as events in the survival analysis. Seven grade-related parameters were scored by one observer. A grading system was constructed using the Cox regression model. The variables in the best-fitting parsimonious model comprised lymphocytic infiltration, tubule configuration and pattern of growth. Scores were derived from the model and a four grade system was created in which the groups were of similar size. Good reproducibility of the selected histopathological parameters was demonstrated. Grade-related parameters were then allowed to compete with stage-related parameters in an overall model of pathological prognostic categories. The parameters selected in the best model were number of affected lymph nodes, the presence of lymphocytic infiltration and extent of spread through bowel wall. A set of five prognostic categories was developed from this model.

Entities:  

Mesh:

Year:  1986        PMID: 3721406     DOI: 10.1111/j.1365-2559.1986.tb02497.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  107 in total

1.  Colorectal Cancer OncoGuia: surgical pathology report guidelines.

Authors:  Xavier Sanjuán; Antonio Salas; Josep Lloreta; Paula Manchon Walsh
Journal:  Clin Transl Oncol       Date:  2010-03       Impact factor: 3.405

2.  Systematic review of prognostic importance of extramural venous invasion in rectal cancer.

Authors:  Manish Chand; Muhammed R S Siddiqui; Ian Swift; Gina Brown
Journal:  World J Gastroenterol       Date:  2016-01-28       Impact factor: 5.742

3.  p27 cell-cycle inhibitor is inversely correlated with lymph node metastases in right-sided colon cancer.

Authors:  D F Liu; K Ferguson; G S Cooper; W M Grady; J Willis
Journal:  J Clin Lab Anal       Date:  1999       Impact factor: 2.352

4.  Recommendations for the reporting of surgically resected specimens of colorectal carcinoma.

Authors:  Jeremy R Jass; Michael J O'Brien; Robert H Riddell; Dale C Snover
Journal:  Virchows Arch       Date:  2006-11-25       Impact factor: 4.064

5.  Expression and significance of Tie-1 and Tie-2 receptors, and angiopoietins-1, 2 and 4 in colorectal adenocarcinoma: Immunohistochemical analysis and correlation with clinicopathological factors.

Authors:  Toshiyuki Nakayama; Go Hatachi; Chun-Yang Wen; Ayumi Yoshizaki; Kazuyuki Yamazumi; Daisuke Niino; Ichiro Sekine
Journal:  World J Gastroenterol       Date:  2005-02-21       Impact factor: 5.742

6.  Clinical importance of DNA content in rectal cancer measured by flow cytometry.

Authors:  J R Jass; K Mukawa; H S Goh; S B Love; D Capellaro
Journal:  J Clin Pathol       Date:  1989-03       Impact factor: 3.411

7.  Invasive front of colorectal cancer: dynamic interface of pro-/anti-tumor factors.

Authors:  Inti Zlobec; Alessandro Lugli
Journal:  World J Gastroenterol       Date:  2009-12-21       Impact factor: 5.742

8.  Regional lymph node metastasis and locoregional recurrence of rectal carcinoma in the era of TME [corrected] surgery. Implications for treatment decisions.

Authors:  Paul Hermanek; Susanne Merkel; Rainer Fietkau; Claus Rödel; Werner Hohenberger
Journal:  Int J Colorectal Dis       Date:  2009-12-10       Impact factor: 2.571

9.  The pathologist's role in rectal cancer patient assessments.

Authors:  Joseph E Willis
Journal:  Clin Colon Rectal Surg       Date:  2007-08

Review 10.  Pathologic prognostic factors for gastrointestinal cancer.

Authors:  T Ismail; M T Hallissey; J W Fielding
Journal:  World J Surg       Date:  1995 Mar-Apr       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.